Clinical value of Alzheimer's disease biomarker testing.
Khushbu J PatelDavid YangJohn R BestColleen ChambersPhilip E LeeAlexandre Henri-BhargavaClark R FunnellDean J FotiJacqueline A PettersenHoward H FeldmanHaakon Berge NygaardGing-Yuek Robin HsiungMari L DeMarcoPublished in: Alzheimer's & dementia (New York, N. Y.) (2024)
AD biomarker testing was associated with significant and positive changes in clinical management, including decreased health care resource use, therapy optimization, and increased patient and family member counseling. While certain changes in management were linked to the AD biomarker profile (e.g., referral to clinical trials), the majority of changes were independent of baseline clinical presentation and level of cognitive impairment, demonstrating a broad value for AD biomarker testing in individuals meeting the appropriate use criteria for testing.